Table 5.
Univariate and multivariate analyses of factors associated with overall survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Serum albumin < 3.7 mg/dL | 3.012 (1.674–5.419) | < 0.001 | ||
| ALBI grade ≥ 2 | 2.216 (1.328–3.699) | 0.002 | ||
| Pathologic mUICC stage (III, IVa) | 3.167 (1.980–5.066) | < 0.001 | 3.118 (1.682–5.782) | < 0.001 |
| Multiple tumorsa | 4.004 (2.181–7.352) | < 0.001 | ||
| Surgical margin involvement | 6.013 (2.980–12.135) | < 0.001 | 4.847 (1.875–12.532) | 0.001 |
| Venous/lymphatic involvement | 2.442 (1.490–4.002) | < 0.001 | ||
| Serosa invasion | 5.083 (2.321–11.132) | < 0.001 | ||
| Bile duct invasion | 7.365 (1.799–30.152) | 0.005 | ||
| Multicentricity | 2.391 (1.305–1.380) | 0.005 | ||
| Satellite nodule | 2.243 (1.329–3.786) | 0.002 | ||
| Tumor necrosis | 2.173 (1.307–3.612) | 0.003 | ||
| Sum of tumor size > 7 cm | 3.224 (1.881–5.526) | < 0.001 | ||
| Beyond Milan criteria | 2.486 (1.548–3.991) | < 0.001 | 2.242 (1.191–4.219) | 0.012 |
| Presence of EHR | 3.994 (2.495–6.395) | < 0.001 | 4.723 (2.512–8.882) | < 0.001 |
HR hazards ratio, CI confidence interval, mUICC modified Union for International Cancer Control, EHR extrahepatic recurrence.
aNumber of tumors examined at pathologic findings.